Psychedelic Weekly Headlines | August 5th

August 5, 2022

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

Braxia Scientific ($BRAX | $BRAXF) acquired KetaMD, an innovative telemedicine company focused on providing technology-facilitated ketamine-based treatments for mental health conditions. KetaMD's technology will provide Braxia the opportunity to offer in-person and digital telehealth ketamine treatments. Press Release

PharmAla Biotech ($MDMA) became an exclusive MDMA supplier to InterVivo Solutions, their client companies and affiliates. InterVivo Solutions is a pre-clinical contract research organization with expertise in neuropsychiatric and neurological diseases. Press Release

Small Pharma ($DMT | $DMTTF) has been granted a Canadian patent protecting Composition of Matter of certain deuterated analogues of DMT, including the active ingredient in their deuterated DMT candidate, SPL028.Press Release

Field Trip Health ($FTRP) received conditional listing approval from the TSX Venture Exchange for listing of common shares of Field Trip Health & Wellness. Field Trip expects Field Trip Health & Wellness Shares to begin trading on August 17, under the symbol 'FTHW'. Press Release

PharmaDrug ($PHRX | $LMLLF) announced a non-brokered offering of $650,000 of convertible secured debentures and issuances of common shares.Press Release

Mind Medicine ($MNMD | $MMED) will participate in the Canaccord Genuity 42nd Annual Growth Conference and announced that their Board of Directors has approved a 1-for-15 reverse share split of their common shares. Details


Psychedelic Finance: Interview With Julia Joyes Of TheraPsil

INN: Morgan Stanley Releases Positive Insights Report on Psychedelics

New York Post: Aaron Rodgers Says Psychedelics Led To 'Best Season Of My Career'

NBC: Oregon Psilocybin Services to finalize rules around administration, production in December 2022

National Post: Canadian Patients Fighting For Psilocybin Access Sue Federal Government

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.